• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

FDA's Pharmacy Compounding Advisory Committee considering a bulk drug substance used for ME/CFS

mango

mango

Senior Member
Messages
905
"On March 8, 2016, the Pharmacy Compounding Advisory Committee will discuss six bulk drug substances nominated for inclusion on the section 503A bulk drug substances list. FDA will discuss the following nominated bulk drug substances: Quinacrine hydrochloride, boswellia, aloe vera 200:1 freeze dried, D-ribose, chondroitin sulfate, and acetyl-L-carnitine. D-ribose has been nominated for inclusion on the list of bulk drug substances for use in compounding for use in the treatment of heart disease and myalgic encephalomyelitis/chronic fatigue syndrome.

Additional information can be found at the following web link:"

http://www.fda.gov/AdvisoryCommitte...acyCompoundingAdvisoryCommittee/ucm486094.htm
 
You must log in or register to reply here.